<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107962</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2017</org_study_id>
    <nct_id>NCT03107962</nct_id>
  </id_info>
  <brief_title>Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma</brief_title>
  <official_title>PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of PD-1 blockade&#xD;
      pembrolizumab for patients with relapsed or refractory Natural Killer(NK)/T Cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with relapsed or refractory NK/T cell lymphoma usually have a bad prognosis. These&#xD;
      patients cannot be treated successfully with the conventional chemotherapy. The investigators&#xD;
      have been proceeding this trial to evaluate the efficacy and safety of the immune checkpoint&#xD;
      inhibitor PD-1 blockade, pembrolizumab in the patients with relapsed or refractory NK/T cell&#xD;
      lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 19, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>every 6 weeks, up to completion of treatment (approximately 18 weeks, unless the disease progresses or patients cannot tolerate the drug)</time_frame>
    <description>21 days (3 weeks) for one cycle, Efficacy was evaluated every two cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to the date of death (approximately 3 years)</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival time</measure>
    <time_frame>2 years</time_frame>
    <description>Median survival time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>PD-1 Blocking Antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab (PD-1 Blocking Antibody)</intervention_name>
    <description>pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.</description>
    <arm_group_label>PD-1 Blocking Antibody</arm_group_label>
    <other_name>Pembrolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time &gt; 3&#xD;
             months&#xD;
&#xD;
          -  Histological confirmed evidence of relapsed or refractory NK/T cell lymphoma&#xD;
&#xD;
          -  Before enrollment, representative formalin-fixed paraffin-embedded tumor samples (or&#xD;
             15 tissue sections at least) and related pathological reports are needed&#xD;
&#xD;
          -  Previous treatment with at least one chemotherapy regimen&#xD;
&#xD;
          -  At least one measurable lesion&#xD;
&#xD;
          -  None of other serious diseases, cardiopulmonary function is normal&#xD;
&#xD;
          -  Pregnancy test of women at reproductive age must be negative&#xD;
&#xD;
          -  Patients could be followed up&#xD;
&#xD;
          -  None of other relative treatments including the traditional Chinese medicine,&#xD;
             immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic&#xD;
             treatments.&#xD;
&#xD;
          -  volunteers who signed informed consent.&#xD;
&#xD;
          -  No anti-PD1 antibody contraindication (All of the following tests are required to be&#xD;
             finished within 14 days prior to the first research): 2.5×109/L&lt;WBC&lt;15×109/L,&#xD;
             hemoglobin ≥ 90 g/L, neutrophil≥ 1.5×109/L, lymphocyte≥0.5×109/L, platelet ≥&#xD;
             100×109/L, serum albumin≥2.5g/dL, ALT and AST ≤ 2×ULN, serum bilirubin≤ 1.5×ULN, serum&#xD;
             creatine ≤ 1.5×ULN, Serum Albumin ≥ 30g/L, serum plasminogen is normal, creatinine&#xD;
             clearance rate≥30 mL/min, INR≤1.5×ULN, APTT≤1.5×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disagreement on blood sample collection&#xD;
&#xD;
          -  Patients allergic of chimeric or humanized antibody&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Serious medical illness likely to interfere with participation&#xD;
&#xD;
          -  Serious infection&#xD;
&#xD;
          -  Primitive or secondary tumors of central nervous system&#xD;
&#xD;
          -  The evidence of CNS metastasis&#xD;
&#xD;
          -  History of peripheral nervous disorder or dysphrenia&#xD;
&#xD;
          -  History of active autoimmune disease and a concomitant second cancer&#xD;
&#xD;
          -  patients participating in other clinical trials&#xD;
&#xD;
          -  patients taking other antitumor drugs&#xD;
&#xD;
          -  patients estimated to be unsuitable by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>mingzhi_zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>NK/T cell lymphoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>clinical trial</keyword>
  <keyword>RR</keyword>
  <keyword>PFS</keyword>
  <keyword>OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

